37
CHAPTER 4: Immunohistochemistry
Conclusion
ALK IHC assays are currently being validated and standardized and appear to be a promising clinical tool for cost-effective screening for the presence of ALK-rearrangement in NSCLC. The procedure is already recommended by organizations in Europe, Japan, and Asia. In the United States, where treatment of NSCLC with an ALK inhibitor is currently dependent on positive results on ALK FISH, positive results on ALK IHC still require verification by ALK FISH for eligibility for ALK inhibitor therapy. However, in the near future, the IHC test may be approved by the US FDA, and patients with positive results on ALK IHC would also be eligible for treatment with an ALK inhibitor. In Europe, ALK-positive lung cancer ????????????????????????1,?%M ?((0